Wegovy injection: dosage, studies and costs at a glance

By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 8 November 2026

Wegovy was the first semaglutide injection approved in the EU specifically for weight management – not for diabetes. That is the crucial difference from Ozempic: same active ingredient, different dose, different intended use.

On this page you will learn how treatment works, what the studies really show and what the treatment costs per month.

Why Wegovy was given its own approval

The EMA approved Wegovy in 2022 for adults with obesity (BMI ≥ 30) or overweight with at least one weight-related condition (BMI ≥ 27) – as an addition to dietary change and exercise. The approval was later extended: in patients with overweight and existing cardiovascular disease, Wegovy can also reduce the risk of heart attack and stroke. Adolescents aged 12 and over can be treated under certain conditions as well.

Dosage: five steps up to the target dose

Wegovy is injected once a week under the skin. The slow build-up is deliberate, so the body can adjust to the effect:

  1. 0.25 mg weekly (start-up dose, 4 weeks)
  2. 0.5 mg weekly (4 weeks)
  3. 1.0 mg weekly (4 weeks)
  4. 1.7 mg weekly (4 weeks)
  5. 2.4 mg weekly (maintenance dose)

If a step is poorly tolerated, interim levels can be held longer – this is set out in the treatment plan agreed with the medical team.

What the studies show

The pivotal trial STEP 1 followed nearly 2,000 participants over 68 weeks: on average, treated patients lost about 15 % of their starting weight – placebo participants just over 2 %. NEJM: STEP 1 (2021). The SELECT study additionally showed a reduction of major cardiovascular events by around 20 % in patients with overweight and pre-existing heart disease. NEJM: SELECT (2023).

Costs and reimbursement

As a self-payer, budget roughly 330–480 € per month, depending on dose and pharmacy. Reimbursement is possible when weight-related conditions exist and the approval criteria are met – the decision rests with each individual insurer.

Side effects

Who is Wegovy suitable for?

Adults with obesity or overweight plus a condition such as high blood pressure, type 2 diabetes or sleep apnoea, when diet and exercise alone are not enough. Without medical clearance it is unsuitable with certain gastrointestinal, thyroid or psychiatric conditions. It is worth comparing with Mounjaro (tirzepatide) if maximum efficacy is the priority.

Frequently asked questions about Wegovy

Frequently asked questions

How long can Wegovy be used?

The duration is set by the treating medical team. Studies covered treatment periods beyond one year; long-term use is possible under regular monitoring.

What happens after stopping?

In the STEP 1 extension, many participants regained part of the lost weight. That makes accompanying nutrition and exercise strategies all the more important.

Does Wegovy need to be injected daily?

No, Wegovy is injected once a week. Only the older injection Saxenda is used daily.

Is semaglutide available as a tablet?

Yes – Rybelsus is an oral semaglutide product, but only approved for type 2 diabetes. High-dose oral formats for weight management are under review.

Sources